Date of last revision: March 2026
These Supplementary Terms apply specifically to the Emerald Weight Management Programme and should be read in conjunction with the Emerald General Terms of Sale, which continue to apply in full. Where there is any conflict between these Supplementary Terms and the General Terms of Sale, these Supplementary Terms shall prevail in respect of the Weight Management Programme.
1. DEFINITIONS AND INTERPRETATION
1.1. In these Supplementary Terms, the following definitions apply in addition to those set out in the General Terms of Sale:
(a) "Weight Management Programme" or "Programme" means the clinician-led prescription medication service for weight management offered by Emerald, including the supply of medication, clinical consultations, ongoing clinical oversight, and associated support services.
(b) "Clinical Consultation" means the initial video consultation conducted by a registered clinician to verify your identity, confirm your weight, review your eligibility questionnaire responses, and determine whether treatment is clinically appropriate for you.
(c) "Eligibility Questionnaire" means the online health assessment you are required to complete before accessing the Programme, which collects information about your health history, current medications, allergies, and other clinically relevant details.
(d) "Treatment Plan" means the personalised medication plan recommended by your clinician, including the prescribed medication, starting dose, and titration schedule.
(e) "Pharmacy Partner" means the GPhC-registered pharmacy engaged by Emerald to dispense and deliver medication prescribed under the Programme.
(f) "Maintenance Dose" means the dose at which your clinician determines that continued treatment is appropriate to sustain your progress, following the initial titration period.
2. ELIGIBILITY AND CLINICAL ASSESSMENT
2.1. The Programme is available to adults aged 18 and over who are resident in the United Kingdom and who meet the clinical eligibility criteria as determined by our clinical team.
2.2. To be considered for the Programme, you must complete the Eligibility Questionnaire accurately and in full. You warrant that all information provided in the Eligibility Questionnaire is truthful, accurate, and complete. Providing inaccurate or misleading information may put your health at risk and may result in the immediate termination of your subscription without refund.
2.3. Completion of the Eligibility Questionnaire does not guarantee acceptance onto the Programme. All treatment is subject to clinical suitability as determined by a registered clinician.
2.4. Following payment, you will be required to attend a Clinical Consultation via video call. During the Clinical Consultation, the clinician will:
(a) verify your identity using valid photo identification (passport or driving licence);
(b) confirm your current weight via a live weight check;
(c) review your Eligibility Questionnaire responses; and
(d) determine whether the Programme is clinically appropriate for you.
2.5. If, following the Clinical Consultation, the clinician determines that treatment is not clinically appropriate for you, your subscription will be cancelled and you will receive a full refund of any payments made.
2.6. You must book your Clinical Consultation within 14 days of completing payment. If you fail to book or attend a Clinical Consultation within this period, we reserve the right to cancel your subscription. In such circumstances, a refund will be issued less any applicable administration fee.
2.7. If you are unable to attend your scheduled Clinical Consultation, you may reschedule by using the link provided in your confirmation email. We request at least 24 hours' notice for cancellations or rescheduling. Repeated failure to attend may result in cancellation of your subscription.
3. THE PROGRAMME
3.1. Subject to clinical approval following your Clinical Consultation, the Programme includes:
(a) supply of the prescribed medication at the dose determined by your clinician;
(b) an initial Clinical Consultation (video call) to assess suitability;
(c) ongoing clinical oversight, including dose adjustments where clinically appropriate;
(d) access to the Emerald platform for progress tracking and clinical communication; and
(e) delivery of medication to a UK address.
3.2. The Programme is provided on a rolling monthly subscription basis. Your subscription will renew automatically every 28 days until cancelled by you or terminated by us in accordance with these terms or the General Terms of Sale.
3.3. Medication prescribed under the Programme may include semaglutide (marketed as Wegovy) or tirzepatide (marketed as Mounjaro), or such other clinically appropriate medication as determined by your clinician. The specific medication and dose will be set out in your Treatment Plan.
3.4. Your clinician may recommend changes to your medication type or dose at any time where clinically appropriate. Any change in dose may result in a change to the price of your subscription. We will notify you of any price change before it takes effect, and you will have the opportunity to cancel your subscription before the new price applies.
3.5. You acknowledge that medication may be prescribed off-label where your clinician determines this to be clinically appropriate. Off-label prescribing means the use of a licensed medication for an indication, patient group, or route of administration not specified in the product's marketing authorisation. Your clinician will explain any off-label prescribing before commencing treatment.
4. YOUR OBLIGATIONS
4.1. By participating in the Programme, you agree to:
(a) be the sole user of any medication prescribed to you under the Programme;
(b) read all information provided to you before commencing treatment, including the patient information leaflet supplied with your medication;
(c) use the medication only in accordance with the instructions provided by your clinician;
(d) complete our clinical questionnaire, inform our clinical team promptly of any new health conditions, changes to your existing health conditions, new medications, or any other changes to your medical history that may affect your suitability for the Programme;
(e) stop taking the medication and seek immediate medical advice if you experience any significant side effects, and to notify our clinical team as soon as reasonably practicable;
(f) contact our clinical team if you miss two or more consecutive doses of your medication;
(g) stop taking the medication immediately and notify our clinical team if you become pregnant, suspect you may be pregnant, or begin trying to conceive;
(h) attend any follow-up consultations or check-ins requested by your clinician; and
(i) not obtain the same or similar prescription medication from any other provider while enrolled in the Programme, unless agreed with our clinical team.
4.2. If you are taking oral contraceptives and are prescribed Mounjaro (tirzepatide) or Orlistat, you must use an additional non-oral form of contraception (such as condoms or an intrauterine device) during treatment, as these medications may reduce the effectiveness of oral contraceptives.
5. PRICING AND PAYMENT
5.1. The price of the Programme varies depending on the medication and dose prescribed. Current pricing is displayed on our platform and is confirmed at checkout before you complete your purchase.
5.2. Payment is taken at the point of checkout, before your Clinical Consultation takes place. If, following the Clinical Consultation, you are found to be ineligible for the Programme, a full refund will be issued in accordance with clause 2.5.
5.3. A delivery fee of £5.00 per order applies and is payable in addition to the medication fee. This will be clearly shown at checkout.
5.4. As your dose may change during the course of your treatment (in accordance with your Treatment Plan or upon clinical recommendation), the price of your subscription may increase or decrease accordingly. We will notify you of any price change before your next payment is taken, and you may cancel your subscription before the new price applies.
5.5. Promotional pricing, introductory offers, and discount codes may be offered from time to time. Unless otherwise stated, promotional pricing applies to the first subscription period only. Subsequent subscription periods will be charged at the standard price for your prescribed dose.
5.6. We reserve the right to amend our pricing at any time. Any price changes will be communicated to you in advance and will take effect from your next subscription renewal date. You may cancel your subscription before the new pricing takes effect.
6. DELIVERY
6.1. Medication will be dispatched by our Pharmacy Partner following clinical approval and the issue of a valid prescription. Delivery is available to UK addresses only.
6.2. Medication will not be dispatched until your Clinical Consultation has been completed and your clinician has confirmed that treatment is appropriate for you.
6.3. All medication is delivered in plain, discreet packaging with no external indication of the contents.
6.4. Delivery timescales and the provisions of the General Terms of Sale relating to delivery, failed delivery, and late delivery apply to the Programme.
7. CANCELLATION AND REFUNDS
7.1. You may cancel your subscription at any time by contacting us. Cancellation will take effect at the end of your current subscription period (28 days from your last payment). No further payments will be taken after cancellation takes effect.
7.2. If you cancel before your Clinical Consultation has taken place, you will receive a full refund.
7.3. If you cancel after your Clinical Consultation has taken place and medication has been dispatched, no refund will be provided for the current subscription period. For safety reasons, we are unable to accept the return of prescription medicines.
7.4. If your clinician determines during the course of treatment that the Programme is no longer clinically appropriate for you, your subscription will be cancelled and no further medication will be dispatched. Any payments already taken for the current subscription period will not be refunded.
7.5. The cancellation provisions of the General Terms of Sale (including any applicable cancellation fees for longer-term plans) continue to apply to the Programme.
8. CLINICAL SAFETY AND MEDICATION
8.1. All medication prescribed under the Programme is a prescription-only medicine and is subject to clinical oversight by a registered clinician.
8.2. You acknowledge that all medications carry a risk of side effects. Common side effects associated with the medications prescribed under the Programme include, but are not limited to, nausea, diarrhoea, constipation, and abdominal discomfort. Full details of potential side effects are set out in the patient information leaflet provided with your medication.
8.3. Our clinical team is available to support you in managing side effects and may adjust your dose or recommend alternative treatment where clinically appropriate.
8.4. You must not take medication prescribed under the Programme in combination with any other prescription weight management medication (including but not limited to other GLP-1 receptor agonists, Saxenda, or Orlistat) unless specifically advised to do so by your Emerald clinician.
8.5. You must store your medication in accordance with the instructions provided. Medication requiring refrigeration must be stored at 2–8°C until use. We accept no liability for medication that has been improperly stored.
8.6. Medication is prescribed for your personal use only. You must not share, sell, transfer, or otherwise make available your medication to any other person. Doing so is a criminal offence and will result in the immediate termination of your subscription.
9. DATA AND YOUR EMERALD HEALTH PROFILE
9.1. If you are an existing Emerald member, data collected through the Programme (including your weight, treatment progress, and clinical notes) may be integrated into your Emerald health profile to provide you with a more comprehensive view of your health. This integration is subject to your consent, which you may withdraw at any time.
9.2. If you are not an existing Emerald member, you may use the Programme as a standalone service. You are not required to hold an Emerald membership to participate in the Programme.
9.3. All personal and health data collected through the Programme will be processed in accordance with our Privacy Policy and applicable data protection legislation.
10. GP NOTIFICATION
10.1. During the Eligibility Questionnaire, you will be asked whether you consent to our sharing information about your treatment with your NHS GP. We strongly recommend that you consent to this, as it ensures your GP has a complete picture of your medical history and can provide you with safe and appropriate care.
10.2. If you decline to share information with your GP, you acknowledge that this may affect the quality and safety of care you receive from other healthcare providers who do not have access to your full medical history.
11. LIMITATION OF LIABILITY
11.1. The provisions of the General Terms of Sale relating to our liability continue to apply in full.
11.2. Without prejudice to clause 11.1, we do not guarantee any particular outcome from the Programme, including any specific amount of weight loss. Individual results vary and depend on a range of factors including your adherence to the Treatment Plan, your diet, your level of physical activity, your medical history, and your individual biological response to the medication.
11.3. The Programme is not a substitute for advice from your NHS GP or other healthcare provider. If you have medical conditions or concerns that are not related to your use of the Programme, you should consult your GP.
12. GENERAL
12.1. These Supplementary Terms are governed by the laws of England and Wales.
12.2. All other provisions of the General Terms of Sale continue to apply to the Programme, including (without limitation) provisions relating to our use of AI tools, third-party diagnostic providers, written communications, intellectual property, and dispute resolution.
12.3. If any provision of these Supplementary Terms is found to be invalid or unenforceable, the remaining provisions shall continue in full force and effect.
